主要先進国における胃腸治療薬市場（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Gastrointestinal Therapeutics in Major Developed Markets – Introduction 11
2.1 Irritable Bowel Syndrome 11
2.1.1 Classification 11
2.1.2 Symptoms 11
2.1.3 Etiology 11
2.1.4 Pathophysiology 12
2.1.5 Diagnosis 12
2.1.6 Epidemiology 13
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Ulcerative Colitis 15
2.2.1 Classification 15
2.2.2 Symptoms 16
2.2.3 Etiology 16
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 17
2.2.6 Epidemiology 18
2.2.7 Prognosis 18
2.2.8 Treatment Options 19
2.3 Crohn’s Disease 20
2.3.1 Classification 20
2.3.2 Symptoms 21
2.3.3 Etiology 21
2.3.4 Pathophysiology 22
2.3.5 Diagnosis 22
2.3.6 Epidemiology 23
2.3.7 Prognosis 23
2.3.8 Treatment Options 24
3 Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global) 25
3.1 Irritable Bowel Syndrome 25
3.2 Ulcerative Colitis 25
3.3 Crohn’s Disease 25
3.4 Key Marketed Products 26
3.4.1 Amitiza 26
3.4.2 Humira 27
3.4.3 Remicade 28
3.4.4 Simponi 29
3.4.5 Cimzia 30
3.4.6 Tysabri 31
4 Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis 33
4.1 Irritable Bowel Syndrome 33
4.1.1 Overall Pipeline 33
4.1.2 Pipeline Analysis by Molecule Type 35
4.1.3 Pipeline Analysis by Mechanism of Action 36
4.2 Ulcerative Colitis Pipeline 38
4.2.1 Overall Pipeline 38
4.2.2 Pipeline Analysis by Molecule Type 40
4.2.3 Pipeline Analysis by Mechanism of Action 41
4.3 Crohn’s Disease Pipeline 43
4.3.1 Overall Pipeline 43
4.3.2 Pipeline Analysis by Molecule Type 45
4.3.3 Pipeline Analysis by Mechanism of Action 46
4.4 Promising Drug Candidates in the Pipeline 48
4.4.1 GSK-1605786 48
4.4.2 MLN0002 48
4.4.3 EMD-61753 48
5 Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019 49
5.1 Major Developed Markets 49
5.1.1 Treatment Usage Patterns 49
5.1.2 Annual Cost of Therapy 49
5.1.3 Market Size 49
5.2 US 51
5.2.1 Treatment Usage Patterns 51
5.2.2 Annual Cost of Therapy 51
5.2.3 Market Size 51
5.3 Europe 53
5.3.1 Treatment Usage Patterns 53
5.3.2 Annual Cost of Therapy 53
5.3.3 Market Size 53
5.4 Canada 55
5.4.1 Treatment Usage Patterns 55
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 55
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Annual Cost of Therapy 57
5.5.3 Market Size 57
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59
6 Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global) 61
6.1 Deals Analysis 61
6.2 Major Co-Development Deals 63
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn’s Disease 64
6.3 Major Licensing Deals 65
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66
7 Gastrointestinal Therapeutics in Major Developed Markets – Appendix 67
7.1 All Pipeline Drugs by Phase 67
7.1.1 Discovery 67
7.1.2 Preclinical 67
7.1.3 IND/CTA-filed 68
7.1.4 Phase I 69
7.1.5 Phase II 70
7.1.6 Phase III 72
7.1.7 Pre-Registration 72
7.1.8 Undisclosed 73
7.2 Market Forecasts to 2019 73
7.2.1 Major Developed Markets 73
7.2.2 US 74
7.2.3 Canada 75
7.2.4 UK 76
7.2.5 France 77
7.2.6 Germany 78
7.2.7 Italy 79
7.2.8 Spain 80
7.2.9 Japan 81
7.3 Market Definitions 82
7.4 Abbreviations 82
7.5 Sources 84
7.6 Research Methodology 86
7.6.1 Coverage 86
7.6.2 Secondary Research 86
7.6.3 Primary Research 87
7.6.4 Therapeutic Landscape 87
7.6.5 Geographical Landscape 90
7.6.6 Pipeline Analysis 90
7.7 Expert Panel Validation 90
7.8 Contact Us 90
7.9 Disclaimer 90